Assessment of the preclinical safety of a new chemical entity or biotechnology-derived drug is based on the results of a series of in sitro and in vivo studies designed to demonstrate the potential toxicity of a compound. The reports that document the results of these studies become part of larger documents (IND/NDA/HRD) that incorporate all of the preclinical safety reports and summarize, and ultimately characterize, the preclinical safety of a compound. To aid this process requires that the report for each study be complete, conservatively interpreted, and clearly written.
Assessment of the preclinical safety of a new chemical entity or biotechnology-derived drug is based on the results of a series of in sitro and in vivo studies designed to demonstrate the potential toxicity of a compound. The reports that document the results of these studies become part of larger documents (IND/NDA/HRD) that incorporate all of the preclinical safety reports and summarize, and ultimately characterize, the preclinical safety of a compound. To aid this process requires that the report for each study be complete, conservatively interpreted, and clearly written.
Preparation of the individual toxicology report provides the writer(s) with the vehicle with which to communicate his/her/their interpretations of the results of the study. However, the writer(s) of the individual report must realize that the safety assessment for a compound is based on the results of a series of studies conducted in both rodent and nonrodent species and is not based on the results of a single study. The assessment is based on the results of studies that vary in length from those using a single high dose to studies that include daily dosing in carcinogenicity studies for 24 mo. These studies are complimented by in vitro and iii vivo genetic toxicity studies and a series of reproduction studies that evaluate effects on reproductive performance of both male and female, potential teratogenicity in the offspring and effects on parturition and the postpartum development of the offspring. THE TOXICOLOGY REPORT:
The report for the individual toxicity study documents in detail the methods used to conduct the study and reviews and interprets for the reader the important findings from the study. When the final report is in the process of being written one should keep in mind its purpose and how it will be used, who will read it, the message it will deliver, and who will make judgments based on its contents. Among the readers of an individual report could be a physician, a manager, a regulatory reviewer, or even an attorney. The reader could be the physician who will first give the compound to a human and is looking for assurance of the safety of the drug or who is reviewing those parameters that he/she can use as indicators of a developing toxicity.
Results from an individual study, if severe or unique, may be used by corporate management to make a decision to discontinue the development of a compound. If the compound has already been administered to humans, this decision may be followed by notification of regulatory agencies as well as physicians involved in clinical trials. Patients will be informed and plans may have to be made to monitor the health of patients over some extended period of time. Thus, in this situation an individual report can be most important in the decision-making process.
The reader may be a science or medical writer who is charged with the responsibility of assembling the first drafts of the NDA or HRD document or the physicians' brochure or package insert.
The reader may be a regulatory reviewer either in the government of the country of the sponsoring company or in a foreign regulatory agency. The reviewer may even be working with translated materials.
Finally, the readcr may be an attorney who is representing either the company or a complainant in litigation against the company based on some alleged adverse effect of the drug. Thus, the care with which the report is prepared and the results interpreted becomes extremely important.
The individual reports and the documents (IND, NDA, HRD, expert reports, physicians' brochures, and package inserts) that ultimately will summarize them are likely to be reviewed by individuals with varying academic backgrounds both within the 202 company and in regulatory agencies in many different countries of the world. These reviews may take place years after most studies have been reported. Not infrequently, the individuals who conducted the studies are no longer members of the organization at the time these reviews take place. Thus, the individual report must be written in such a way and the supporting data recorded and archived with sufficient care that years after the study has been completed and reported it will be possible to reconstruct the study and the events that surrounded its conduct.
For the preceding reasons, the study report that documents the results of a toxicology study differs markedly from a paper written for publication. The study report is significantly more detailed and has a number of components that are required to be present that normally would not be included in a report prepared for a publication.
THE MATERIALS AND METHODS SECTION The materials and methods section ofa toxicology report must include sufficient details and information to make it possible to reconstruct specific aspects of a study should it become necessary at some point in the future. Thus, such details as the date the study was initiated and the date the study was terminated must be included in the materials and methods section. Details must be included about the species and strain of animal used; their source; age and weights at start of dosing; how they were acclimated, housed, and watered; and their diet and how it was administered. Information must be included on laboratory conditions of temperature and humidity and how the animals were randomized. Information relating to study design must include information on doses, dose concentrations, dose volumes, the composition of the vehicle, the composition of the formulated material, and the purity of the drug substance that was administered. The dosing duration, route, and frequency is required. Information documenting the batch numbers for the test article, the vehicle, and the positive control are necessary. The use of the animal model,.the route of compound administration, and the doses used must bejustified. The method used in the statistical evaluation of the data must be presented and referenced.
The preceding level of detail is required in the materials and methods section for several reasons. The first is to make it possible to completely reconstruct the study and its data should questions arise in the future. The second is to make it possible to select appropriate comparative control data for the data generated in the study should that need arise. Examples ofthe comparative control data one might wish to access include control tumor data for a given organ and tumor type gathered in the same laboratory at or around the time the study in question was being conducted [n the same species, sex, and strain of animal. Another example would be the selection and use of appropriate comparative control data collected in clinical pathology using the same assay method as that in the study in question.
THE RESULTS SECTION
In the results section of the report, details on the individual components of the study are presented. The results section should be designed to accurately and completely present to the reader all the data and should organize and summarize it in a manner that is clear, concise, and logical.
For efficiency and to avoid unnecessary and wasteful rewriting of reports, the format must be consistent from report to report. Although this format will vary among companies, a procedure that is useful in presenting the results of a study is first to give, by dose, all the findings in the animals that died or were sacrificed prior to'the scheduled termination of the study. This is then followed by a presentation, by dose, of the clinical signs, the clinical pathology, the gross pathology, the organ weights, and the microscopic pathology. By convention it is best to use a consistent format for refemng to the different dose groups, either consistently beginning with the low dose or consistently beginning with the high dose. One thing thatis helpful to the reader is to consistently refer to the dose group by the quantity of compound delivered. This simple practice makes it significantly easier for the reader to keep the information related to dose organized in hidher mind than does reference to the groups as the low-, mid-, and high-dose groups. Reference to effects by low-, mid-, and high-dose groups or Groups 1, 2, and 3 are not helpful to the reader, and if it is necessary to switch back and forth between reports it can be very confusing.
Further, it is important that the writer(s) only concentrate on those findings that in the opinion of the writer(s) represent effects produced by the compound. The writer(s) must make the presentation of these facts clear and succinct. If the results are complicated, this information is most easily presented by the incorporation of a text table to present the specific piece of data. Using this process, the writer($ only has to point out to the reader the facts that he/she/they deem to be important and does not go through a long and detailed written description of the findings.
In the results section, the significance of findings may be interpreted for the reader as they are presented based on other information either in the lit-BLACK TOXICOLOGIC PATHOLOGY erature or in reports ofother studies conducted with the drug. For example, reference may be made to similar findings having been reported with other compounds of a similar class or structure. The evaluation of organ weight data can be difficult, particularly if group sizes are too small to permit statistical evaluation. In such circumstances it is useful to only refer to those findings where both the absolute and the relative values fall outside the range for the controls to avoid apparent changes that really reflect the effect of changes in body weights. However, it is important that the writer relate to the reader hidher interpretation of the significance of findings that may appear with a relatively high incidence but are incidental findings in the study. It is useful if the presenter can back this interpretation with a literature reference.
Confusion can be quickly introduced into a pathology report by a detailed description of a lesion that only at the end of the description is revealed to have occurred with equal frequency in both the dosed and the control groups. If a lesion appears to be related to the method of compound administration and not to the compound, the findings should be introduced as such and only then described to the reader.
The writer(s) must be careful with the use of allinclusive statements in the results section. For example, a statement that says "no other compoundrelated lesions were observed" says that everything described prior to the statement should be considered by the reader to be compound-related. Frequently, that is not the intention of the writer when making such a statement. A statement that a finding is without "biological" or "toxicological" significance should only be made if the writer@) is going to follow the statement with reasoning that justifies that conclusion.
It is important that the writer(s) relate to the reader his/her/their interpretation of the significance of findings that may appear with a relatively high incidence but are considered by the writer to be incidental findings in the study. It is useful if the writer($ can back this interpretation with . specific examples or literature reference(s).
THE EVALUATION SECTION
In organizing and presenting the results of the study, the writer@) must keep in mind what message he/she/they wishes to communicate to the reader. This can be accomplished very nicely by concluding a toxicology report with an evaluation section. Im; portant points that should come out in the.evaluation section of any report are as follows. How well was the drug tolerated clinically by the animals and up to what multiple ofthe administered clinical dose?
What were the target organs of toxicity? What were the important points developed by the blood level data; i.e., was there any evidence of drug accumulation or any suggestion of induction of drug metabolizing enzymes and, if so, at what dose? What was the "no-effect dose" in the study? In the evaluation section, it is also appropriate to document whether similar findings to those observed in the study have been reported with the compound in other species or other studies or whether similar findings have been observed with compounds of a similar structure or class. Conclusions of this nature require that the writer(s) document, by specific reference, the data that justifies the statement.
Finally, the report'must, evaluate the significance of the findings for humans and whether they do or do not support the continued development of the drug.
ACCOMPANYING DOCUMENTATION
In addition to the introduction and the detailed materials and methods and results sections, the toxicology report is accompanied by other supporting pieces of information that would not appear in a paper for publication. These include (a) a signed protocol, (b) all signed protocol amendments, (c) a quality assurance statement that lists inspection dates and portions of study inspected, (d) a certificate of analysis for the test article, (e) a list of individuals responsible for each segment of the study, and (0 signed, individual anatomic pathology, clinical pathology, ophthalmology, and cardiology reports. Also in the report are summary tables ofthe clinical signs, body weights, food consumption, hematology, clinical chemistry, urinalysis, urine chemistries, organ weights, and gross and microscopic changes, whether they represent drug-related effects or not. Supporting the written and the summary tabular data is all of the individual animal raw data.
REVIEW OF THE D R A~ TOXICOLOGY REPORT
Preparation of the final report is a laborious task if done correctly, and the final product must be an accurate and a complete presentation of the facts. Because the toxicology report presents results generated by individuals who have very different areas of expertise, it i's most effective for the individuals responsible for specific disciplines to write their report($ first. These reports can then be incorporated into a draft of the final document. The draft of the final report should be reviewed individually by all contributors and then is reviewed in a report review meeting with all contributors present. This format facilitates the discussion and questioning of individual statements and interpretations of the data. This format also prevents any one individual from
